Compare LOOP & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOOP | ACET |
|---|---|---|
| Founded | 2010 | 1947 |
| Country | Canada | United States |
| Employees | N/A | 102 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.7M | 33.5M |
| IPO Year | 2010 | 2017 |
| Metric | LOOP | ACET |
|---|---|---|
| Price | $0.26 | $3.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $2.30 | ★ $34.83 |
| AVG Volume (30 Days) | 104.6K | ★ 187.5K |
| Earning Date | 10-15-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,889,000.00 | N/A |
| Revenue This Year | $63.62 | N/A |
| Revenue Next Year | $735.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7016.99 | N/A |
| 52 Week Low | $0.24 | $0.46 |
| 52 Week High | $1.73 | $9.97 |
| Indicator | LOOP | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 32.42 | 18.83 |
| Support Level | N/A | N/A |
| Resistance Level | $0.48 | $9.59 |
| Average True Range (ATR) | 0.03 | 0.34 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 17.75 | 3.39 |
Loop Industries Inc is a technology company whose mission is to accelerate the world's shift toward sustainable PET plastic and polyester fiber and away from dependence on fossil fuels. Loop Industries owns patented and proprietary technology that depolymerizes no and low-value waste PET plastic and polyester fiber, including plastic bottles, packaging, and textiles such as carpets and clothing, into its base building block monomers, DMT and MEG.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).